Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Polatuzumab Outperforms Pinatuzumab in Non-Hodgkin Lymphoma
Key clinical point: Polatuzumab vedotin plus rituximab (R-pola) produced more durable responses than did pinatuzumab vedotin plus rituximab (R-pina) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) or follicular lymphoma (FL).
Major finding: The median duration of response was 6.2 months in the DLBCL R-pina arm, 13.4 months in the DLBCL R-pola arm, 6.5 months in the FL R-pina arm, and 9.4 months in the FL R-pola arm.
Study details: A phase 2 trial of 81 DLBCL patients and 42 FL patients.
Disclosures: F. Hoffmann-La Roche funded the trial. The authors reported relationships with Roche and other companies.
Morschhauser F et al. Lancet Haematol. 2019 Mar 29. doi: 10.1016/S2352-3026(19)30026-2.